Description
Decursin is a phytochemical originally isolated from
A. gigas with diverse biological activities. It reduces the growth of B16/F10 murine melanoma cells, but not NIH-3T3 fibroblasts,
via induction of apoptosis and increased caspase-3 activity when used at concentrations ranging from 40 to 100 μM.
In vivo, decursin (10 mg/kg, i.p.) reduces tumor growth in a B16/F10 mouse xenograft model. Decursin inhibits RANKL-induced osteoclast differentiation and decreases fusion and migrations of pre-osteoclasts
in vitro and prevents LPS-induced bone erosion in mice. In a mouse model of seizures induced by kainic acid , decursin (20 mg/kg) increases latency to the first electroencephalographic (EEG) discharge and attenuates the intensity and reduces the frequency of seizure discharges in the parietal cortex. Decursin inhibits tube formation and expression of VEGF receptor 2 (VEGFR2) in human retinal microvascular endothelial cells (HRMECs) and human umbilical vein endothelial cells (HUVECs)
in vitro and reduces retinal expression of VEGFR2 and neovascularization in rats with diabetes induced by streptozotocin . It also reduces hepatic collagen expression, serum levels of ALT, AST, and ALP, and production of reactive oxygen species (ROS) in a mouse model of CCL
4-induced liver fibrosis.
Uses
Decursin is a bioactive metabolites from the root of Angelica gigas Nakai which exhibits neuro-protective and cognitive enhancement effects. Human monoamine oxidase (MAO) inhibitor. Also, it could be useful for the treatment of bone associated with excessive bone resorption.
Definition
ChEBI: Decursin is a member of coumarins.
Biochem/physiol Actions
Decursin is a cumarin isolated from Radix peucedani that exhibits a number of physiological actions including anticancer, antibacterial, antinematodal and antioxidant. Decursin is potent anti-angiogenic agent targeting the VEGFR-2 signaling pathway. Decursin exhibits potent neuroprotective activity against glutamate and Ab- induced neurotoxicity. Apparently, decursin stimulates activation of Nerf2. Also, decursin inhibits androgen stimulated AR translocation to the nucleus in LNCaP prostate cancer cells.
Side effects
It is important to note that Decursin has not been approved by the FDA for any medical use and there is limited research on its safety and effectiveness. Possible side effects of Decursin include nausea, vomiting, diarrhea, abdominal pain, dizziness, headache, and rash. It may also interact with certain medications, so it is important to consult with a healthcare professional before taking Decursin. Additionally, Decursin may not be safe for pregnant or breastfeeding women, as well as those with certain medical conditions.
target
NADPH-oxidase | TGF-β/Smad | AChR | NF-kB | MMP(e.g.TIMP) | p38MAPK | PKC | p53 | P450 (e.g. CYP17) | VEGFR | JNK | LTR | IL Receptor | TNF-α
